Nuvalent, Inc. (NASDAQ: NUVL) related to its sale to GSK plc. Under the terms of the proposed transaction, Nuvalent shareholders are expected to receive $124.00 per share in cash.
Nuvalent, Inc. (NASDAQ: NUVL) related to its sale to GSK plc. Under the terms of the proposed transaction, Nuvalent shareholders are expected to receive $124.00 per share in cash.